AU2008335668C1 - 6, 11-bridged biaryl macrolides - Google Patents

6, 11-bridged biaryl macrolides Download PDF

Info

Publication number
AU2008335668C1
AU2008335668C1 AU2008335668A AU2008335668A AU2008335668C1 AU 2008335668 C1 AU2008335668 C1 AU 2008335668C1 AU 2008335668 A AU2008335668 A AU 2008335668A AU 2008335668 A AU2008335668 A AU 2008335668A AU 2008335668 C1 AU2008335668 C1 AU 2008335668C1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
hydrogen
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008335668A
Other languages
English (en)
Other versions
AU2008335668A1 (en
AU2008335668B2 (en
Inventor
Heejin Kim
In Jong Kim
Tongzhu Liu
Jiang Long
Yat Sun Or
Ly Tam Phan
Yao-Ling Qiu
Guoqiang Wang
Yanchun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Enanta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharmaceuticals Inc filed Critical Enanta Pharmaceuticals Inc
Publication of AU2008335668A1 publication Critical patent/AU2008335668A1/en
Application granted granted Critical
Publication of AU2008335668B2 publication Critical patent/AU2008335668B2/en
Publication of AU2008335668C1 publication Critical patent/AU2008335668C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2008335668A 2007-09-17 2008-09-17 6, 11-bridged biaryl macrolides Ceased AU2008335668C1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US97301707P 2007-09-17 2007-09-17
US60/973,017 2007-09-17
US97320107P 2007-09-18 2007-09-18
US60/973,201 2007-09-18
US5186208P 2008-05-09 2008-05-09
US5185708P 2008-05-09 2008-05-09
US5187508P 2008-05-09 2008-05-09
US61/051,857 2008-05-09
US61/051,875 2008-05-09
US61/051,862 2008-05-09
US7621308P 2008-06-27 2008-06-27
US7620808P 2008-06-27 2008-06-27
US61/076,213 2008-06-27
US61/076,208 2008-06-27
US9511108P 2008-09-08 2008-09-08
US9510008P 2008-09-08 2008-09-08
US61/095,111 2008-09-08
US61/095,100 2008-09-08
PCT/US2008/076731 WO2009075923A2 (en) 2007-09-17 2008-09-17 6, 11-bridged biaryl macrolides

Publications (3)

Publication Number Publication Date
AU2008335668A1 AU2008335668A1 (en) 2009-06-18
AU2008335668B2 AU2008335668B2 (en) 2012-07-26
AU2008335668C1 true AU2008335668C1 (en) 2013-05-30

Family

ID=40455143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008335668A Ceased AU2008335668C1 (en) 2007-09-17 2008-09-17 6, 11-bridged biaryl macrolides

Country Status (11)

Country Link
US (2) US20090075915A1 (https=)
EP (1) EP2203435B1 (https=)
JP (2) JP5642548B2 (https=)
KR (2) KR101223158B1 (https=)
CN (2) CN101855219B (https=)
AU (1) AU2008335668C1 (https=)
CA (1) CA2699733C (https=)
ES (1) ES2691252T3 (https=)
MX (1) MX2010002932A (https=)
NZ (2) NZ600635A (https=)
WO (2) WO2009075923A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691252T3 (es) * 2007-09-17 2018-11-26 Enanta Pharmaceuticals, Inc. Macrólidos de biarilo con puente en 6,11
US8354383B2 (en) * 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
US8273720B2 (en) * 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
WO2009137787A1 (en) * 2008-05-09 2009-11-12 Enanta Pharmaceuticals, Inc. Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives
US7842813B2 (en) * 2008-05-09 2010-11-30 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
WO2012076989A1 (en) * 2010-12-09 2012-06-14 Wockhardt Limited Ketolide compounds
JP7110094B2 (ja) * 2015-11-19 2022-08-01 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 医薬化合物のアミンプロドラッグ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061525A1 (en) * 2002-05-13 2005-07-07 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85103264A (zh) * 1984-04-13 1987-01-14 美国辉瑞有限公司 9a-氮杂-9a-高红霉素衍生物
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4921836A (en) * 1989-05-17 1990-05-01 Burroughs Wellcome Co. Substituted glutamic acids
IL114589A (en) * 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
EP0559896B1 (en) * 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
US5202434A (en) * 1991-04-05 1993-04-13 Merck & Co., Inc. 8a-aza-8a-homoerythromycin lactams
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
ATE135707T1 (de) * 1992-04-22 1996-04-15 Taisho Pharmaceutical Co Ltd 5-0-desosaminylerythronolid a derivate
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
FR2738571B1 (fr) * 1995-09-11 1997-10-17 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-0-methyl- erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) * 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
DE69733723T2 (de) * 1996-09-04 2006-04-20 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
US5780605A (en) * 1997-09-08 1998-07-14 Abbott Laboratories 6,9-bridged erythromycin derivatives
US6124269A (en) * 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives
US6046171A (en) * 1997-10-29 2000-04-04 Abbott Laboratories 6,11-bridged erythromycin derivatives
PT941998E (pt) * 1998-03-03 2004-12-31 Pfizer Prod Inc Antibioticos macrolidos do tipo 3,6-cetal
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6590083B1 (en) * 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
IL145976A0 (en) * 1999-04-16 2002-07-25 Ortho Mcneil Pharm Inc Ketolide antibacterials
HRP990130B1 (en) * 1999-05-03 2004-06-30 Pliva D D HALOGEN DERIVATIVES 9a-N-(N'-ARYLCARBAMOYL)- AND 9a-N-(N'-ARYLTHIOCARBAMOYL)-9-DEOXO-9a-AZA-9a OF HOMOERYTHROMYCIN A
US6355620B1 (en) * 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
US6764998B1 (en) * 2003-06-18 2004-07-20 Enanta Pharmaceuticals, Inc. 6,11-4C-bicyclic 9a-azalide derivatives
US6753318B1 (en) * 2002-07-25 2004-06-22 Enanta Pharmaceuticals, Inc. 6,11-4-carbon bridged erythromycin derivatives
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US6878691B2 (en) 2002-05-13 2005-04-12 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US6841664B2 (en) * 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
JP3821826B2 (ja) * 2002-05-13 2006-09-13 エナンタ ファーマシューティカルズ インコーポレイテッド ６−１１二環式ケトライド誘導体
US7135573B2 (en) * 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
KR100661973B1 (ko) * 2002-05-13 2006-12-28 이난타 파마슈티칼스, 인코포레이티드 6,11 바이사이클릭 에리스로마이신 유도체
US7022679B2 (en) * 2002-05-13 2006-04-04 Enanta Pharmaceuticals, Inc. Processes for the preparation of 6-11 bicyclic erythromycin derivatives
US6645941B1 (en) * 2003-03-26 2003-11-11 Enanta Pharmaceuticals, Inc. 6,11-3C-bicyclic 9a-azalide derivatives
AU2003295869A1 (en) * 2003-11-20 2005-07-14 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide drivatives
WO2005067564A2 (en) * 2004-01-07 2005-07-28 Enanta Pharmaceuticals, Inc. 6-11 bicyclic erythromycin derivatives
WO2005070113A2 (en) * 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
JP2008508322A (ja) * 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
US7229972B2 (en) * 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060252710A1 (en) * 2005-05-04 2006-11-09 Guoqiang Wang 6-11 Bridged oxime erythromycin derivatives
US7589067B2 (en) 2005-10-12 2009-09-15 Enanta Pharmaceuticals, Inc. 6, 11-bridged tricyclic macrolides
ES2691252T3 (es) * 2007-09-17 2018-11-26 Enanta Pharmaceuticals, Inc. Macrólidos de biarilo con puente en 6,11

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061525A1 (en) * 2002-05-13 2005-07-07 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives

Also Published As

Publication number Publication date
CA2699733A1 (en) 2009-06-18
US20090075915A1 (en) 2009-03-19
NZ600635A (en) 2013-06-28
EP2203435A4 (en) 2011-03-02
JP2015017139A (ja) 2015-01-29
WO2009039177A1 (en) 2009-03-26
JP5642548B2 (ja) 2014-12-17
ES2691252T3 (es) 2018-11-26
CN104004039A (zh) 2014-08-27
CA2699733C (en) 2013-01-22
KR20100059990A (ko) 2010-06-04
US20090118506A1 (en) 2009-05-07
WO2009075923A3 (en) 2009-09-24
NZ584159A (en) 2012-08-31
AU2008335668A1 (en) 2009-06-18
WO2009075923A2 (en) 2009-06-18
KR101223158B1 (ko) 2013-01-17
MX2010002932A (es) 2010-05-27
EP2203435A2 (en) 2010-07-07
KR20120132577A (ko) 2012-12-05
JP2010539191A (ja) 2010-12-16
CN101855219A (zh) 2010-10-06
AU2008335668B2 (en) 2012-07-26
EP2203435B1 (en) 2018-07-18
CN101855219B (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
AU2008335668C1 (en) 6, 11-bridged biaryl macrolides
US8354383B2 (en) 6,11-bridged biaryl macrolides
AU2005314124B2 (en) 3, 6-bicyclolides
WO2005070113A2 (en) 9n-substituted 6-11 bicyclic erythromycin derivatives
US8273720B2 (en) 6,11-bicyclolides: bridged biaryl macrolide derivatives
WO2005067564A2 (en) 6-11 bicyclic erythromycin derivatives
WO2006065721A2 (en) 11, 12-lactone bicyclolides
WO2007044927A2 (en) 6, 11-bridged tricyclic macrolides
WO2006065743A2 (en) Tetracylic bicyclolides
WO2008014221A2 (en) Bridged carbamate macrolides
WO2006078450A1 (en) 9a, 11-2c-bicyclic 9a-azalide derivatives
US7622452B2 (en) C-9 alkenylidine bridged macrolides
WO2005067919A1 (en) 11-csubsituted erythromycin derivatives
WO2008019240A2 (en) 3, 6-bridged tylosin derivatives
CA2531561A1 (en) 11-12 bicyclic erythromycin derivatives
HK1141025A (en) 6, 11-bridged biaryl macrolides
HK1141025B (en) 6, 11-bridged biaryl macrolides
WO2006119384A1 (en) Spirocyclic bicyclolides
WO2009137737A2 (en) Anti-bacterial activity of 9-hydroxy derivatives of 6, 11-bicyclolides
AU2006242188A1 (en) 6-11 bridged oxime erythromycin derivatives
WO2007115278A2 (en) 3,6,11-tricyclolide

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ OR, YAT SUN; WANG, YANCHUN; LIU, TONGZHU; WANG, GUOQIANG; KIM, IN JONG; QIU, YAO-LING; KIM, HEEJIN; LONG, JIANG AND PHAN, LY TAM .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ OR, YAT SUN; WANG, YANCHUN; LIU, TONGZHU; WANG, GUOQIANG; KIM, IN JONG; QIU, YAO-LING; KIM, HEEJIN; LONG, JIANG AND PHAN, LY TAM

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE - 696 - STATEMENT(S) FILED 01 NOV 2012 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 NOV 2012 AND 17 JAN 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired